Effect of apoA‑I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins

• Dennis Pedersbæk,
• Louise Krogager,
• Camilla Hald Albertsen,
• Lars Ringgaard,
• Anders E. Hansen,
• Katrine Jønsson,
• Jannik B. Larsen,
• Andreas Kjær,
• Thomas L. Andresen,
• Jens B. Simonsen

Affiliations

Dennis Pedersbæk

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Louise Krogager

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Camilla Hald Albertsen

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Lars Ringgaard

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Anders E. Hansen

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Katrine Jønsson

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Jannik B. Larsen

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Andreas Kjær

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark

Thomas L. Andresen

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark

Jens B. Simonsen

Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark